

REPORT ON CORPORATE GOVERNANCE*(6 months)***To : - Hanoi Stock Exchange**

- Company name: **Central Pharmaceutical Joint Stock Company No. 3**
- Head office address: **No. 16 Le Dai Hanh Street, Hong Bang Ward, Hai Phong City**
- Phone: **02253 842576**
- Fax: **02253 823125**
- Registered capital: **214,999,330,000 VND**
- Stock ticker symbol: **DP3**
- Company governance model: **General Shareholders' Meeting, Board of Directors, Supervisory Board, General Director**

I. Activities of the General Meeting of Shareholders

No.	Resolution/Decision Number	Day	Content
1	Number: 503/2026/NQ-ĐHĐCĐ	April 24, 2026	Through the report of the Board of Directors and the Executive Board on the business results for 2025 ; the activities of the Board of Directors in 2025 and the business plan for 2026 : <u>Business performance results for 2025:</u> Total revenue: 437,926,922,460 VND Total accounting profit before tax: VND 192,619,250,929 Cash dividend payment for 2025: 40% per share (4,000 VND per share) <u>Business plan for 2026 :</u> Total revenue: 450 billion VND Total accounting profit before tax: 90 billion VND Cash dividends: minimum 20%

			summary financial report for 2025 audited
			Through the proposal regarding the profit distribution plan for 2025
			Through the report number regarding the remuneration of the Board of Directors and the Supervisory Board in 2026
			Through the submission regarding the addition and amendment of industry codes, business lines, and the Company Charter .
			Through the Company's Supervisory Board report for 2025
			Through the Supervisory Board's proposal regarding the selection of an auditing firm for the 2026 financial statements: The General Meeting authorizes the Board of Directors to select one of the following companies to audit/review the 2026 financial statements : Vietnam Auditing and Valuation Company Limited – VAE Address : 11th Floor, Song Da Building , 165 Cau Giay Street, Cau Giay Ward, Hanoi City + Deloitte Vietnam Auditing Company Limited Address : 12th Floor, Diamond Park Plaza Building, 16 Lang Ha Street, Giang Vo Ward , Hanoi City, Vietnam. AASC Auditing Firm Co., Ltd. Address : No. 1, Le Phung Hieu Street, Hoan Kiem Ward , Hanoi City, Vietnam.
			Ms. Lu Thi Khanh Tran from the Board of Directors .
			Through the "Regulations on the supplementary election of Board of Directors members for the 2024-2029 term".
			Through the proposal regarding the approval of the number and list of candidates for the by-election of Board of Directors members for the 2024-2029 term.
			Through the minutes of the Shareholders' General Meeting regarding the results of the election of additional members to the Board of Directors for the term 2024 – 2029. The results are as follows: Mr. Vu Duc Canh - Number of votes: 18,069,344 Percentage: 100% He has been elected as a member of the Board of Directors for the term 2024 – 2029.
	Number : 504 / 2026 / NQ -ĐHĐCĐ	April 24, 2026	1. The General Meeting approved the change of business lines in Business Registration Certificate No.: 0200572501

- Add the following business lines/activities:

No.	Name of industry/business added	Industry code	Main business sector/activities
1.	Production of non-alcoholic beverages and mineral water.	1105	
2.	Manufacture of cosmetics, perfumes, soaps, detergents, polishes and sanitary preparations.	2023	
3.	Other specialized wholesale trade not classified elsewhere Details: Wholesale of general chemicals (excluding those used in agriculture)	4679	
4.	Retail sale of medicines, medical devices, cosmetics and hygiene products.	4772	
5.	Retail sale of other new goods (excluding automobiles, motorcycles, and their accessories) Details: Retail sale of common chemicals (excluding chemicals prohibited by the state); Retail sale of essential oils, medical machinery and equipment.	4773	
6.	Food retail Details: Retail sale of dietary supplements	4722	

- Abandon the business sector/profession. after:

No.	Name of industry/business removed from the registered list	Industry code	Note
1.	Production of non-alcoholic beverages and mineral water.	1104	
2.	Manufacture of cosmetics, soaps, detergents, polishes and sanitary preparations	2023	
3.	Other specialized wholesale trade not classified elsewhere Details: Wholesale of general chemicals (excluding those used in agriculture)	4669	
4.	Retail sale of medicines, medical devices, cosmetics and hygiene products in specialized stores.	4772	

			<table> <tr> <td>5.</td><td>Retail sale of other new goods in specialized stores Details: Retail sale of general chemicals (excluding those used in agriculture); Retail sale of essential oils, medical machinery and equipment.</td><td>4773</td><td></td></tr> <tr> <td>6.</td><td>Retail sale of food in specialized stores Details: Retail sale of dietary supplements</td><td>4722</td><td></td></tr> </table>	5.	Retail sale of other new goods in specialized stores Details: Retail sale of general chemicals (excluding those used in agriculture); Retail sale of essential oils, medical machinery and equipment.	4773		6.	Retail sale of food in specialized stores Details: Retail sale of dietary supplements	4722	
5.	Retail sale of other new goods in specialized stores Details: Retail sale of general chemicals (excluding those used in agriculture); Retail sale of essential oils, medical machinery and equipment.	4773									
6.	Retail sale of food in specialized stores Details: Retail sale of dietary supplements	4722									
2. Amendments and additions to the Company Charter Amend and supplement Article 3, Chapter III of the Company Charter : Business lines and activities in accordance with the content of Article 1 of this Resolution.											

II. Board of Directors (Six-Month Report)

1. Information about the members of the Board of Directors

No.	Board Member	Position	Date of commencement/cessation of membership on the Board of Directors/independent board member	
			Appointment date	Dismissal date
1	Mr. Bui Xuan Huong	Chairman of the Board	April 24, 2024	
2	Mr. Nguyen Dinh Khai	Board Member and CEO	April 24, 2024	
3	Mr. Dinh Van Cuong	Non-executive members of the Board of Directors	April 24, 2024	
4	Ms. Lu Thi Khanh Tran	Non-executive members of the Board of Directors	April 24, 2024	April 24, 2026
5	Mr. Le Van Hung	Non-executive members of the Board of Directors	April 24, 2024	
6	Mr. Vu Duc Canh	Non-executive members of the Board of Directors	April 24, 2026	

2. Board of Directors Meetings

No.	Board Member	Number of Board of Directors meetings attended	Participation rate attend the meeting	Reasons for not attending the meeting.
1	Mr. Bui Xuan Huong	3/3	100%	
2	Mr. Nguyen Dinh Khai	3/3	100%	

No.	Board Member	Number of Board of Directors meetings attended	Participation rate attend the meeting	Reasons for not attending the meeting.
3	Mr. Dinh Van Cuong	3/3	100%	
4	Ms. Lu Thi Khanh Tran	2/3	66.67%	Dismissal date: April 24, 2026
5	Mr. Le Van Hung	2/3	66.67%	Due to work commitments, I have authorized Mr. Nguyen Dinh Khai to vote on the agenda items at the meeting on June 16, 2026.
6	Mr. Vu Duc Canh	1/3	33.3%	By-elections will be held from April 24, 2026.

3. The Board of Directors' oversight of the General Management Board.

Based on the Company Charter and Internal Governance Regulations, the Board of Directors has inspected and supervised the Executive Board's activities in managing production and business operations and implementing the resolutions of the Annual General Meeting of Shareholders in 2025 and 2026. Through the monitoring mechanism and the requirement for periodic and ad hoc reports, the Board of Directors assessed that the Executive Board has performed its assigned tasks in accordance with the law, the Company Charter, the resolutions of the Annual General Meeting of Shareholders, and the resolutions and decisions of the Board of Directors.

The Board of Directors highly appreciates the General Director's effective management in seriously implementing the resolutions of the Board of Directors and the General Meeting of Shareholders, ensuring compliance with internal procedures. The General Director has effectively played his leadership role, providing strategic direction and coordinating operations closely, helping the Company maintain stable growth in a challenging market environment.

The General Director, with extensive experience in the pharmaceutical industry, has effectively and efficiently fulfilled the role and responsibilities of the head of operations, and is also the legal representative.

The company has made full and timely disclosures in accordance with regulations.

4. Resolutions/Decisions of the Board of Directors (6-Month Report)

No.	Resolution/Decision Number	Day	Content	Approval rate
1	Number: 218/NQ-HĐQT	February 2, 2026	Through the 2025 business performance report (unaudited figures).	5/5
			The business plan for 2026 was presented to the Annual General Meeting of Shareholders.	4/5

No.	Resolution/Decision Number	Day	Content	Approval rate
			Through the amendment of "Regulations on Business Operations and Product Consumption" No. 1693/QC-HĐQT dated December 19, 2025.	5/5
			Through the amendment of the "Salary Regulations" No. 1695/QC-HĐQT dated December 19, 2025.	5/5
			Through amendments and additions to the business lines to be submitted to the Annual General Meeting of Shareholders in 2026.	5/5
2	Number: 219/NQ-HĐQT		This includes finalizing the list of shareholders to attend the 2026 Annual General Meeting and paying an interim cash dividend for 2025.	5/5
3	Number: 398/NQ-HĐQT	April 1, 2026	Through the removal of Ms. Lu Thi Khanh Tran from her position as a member of the Board of Directors of Central Pharmaceutical Company No. 3, the matter will be submitted to the 2026 General Meeting of Shareholders for voting and approval.	5/5
4	Number: 419/NQ-HĐQT		Through the Annual General Meeting Documents for 2026.	5/5
5	Number: 742/NQ-HĐQT	June 16, 2026	Through amendments to the content of the "Regulations on Business Operations and Product Sales".	5/5
6	Number: 743/NQ-HĐQT		Through amendments and additions to the content of the "Salary Regulations"	5/5
			Through borrowing capital and mortgaging assets at banks.	5/5
			Through the report of the Chairman of the Board of Directors and the General Director on the situation at the area No. 16 + 18 Le Dai Hanh Street, Hong Bang Ward, Hai Phong City	5/5
			Through the policy of gradually promoting the construction of a GMP-EU standard herbal medicine manufacturing plant at Lot N1-2, Trang Due Industrial Park, An Phong Ward, Hai Phong City, the General Director is tasked with developing the methods and plans to be submitted to the Board of Directors before being presented to the General Meeting of Shareholders for approval.	5/5
7	Number: 744/NQ-HĐQT		The Board of Directors has decided to select the auditing firm to conduct the review and audit of the 2026 financial statements as follows: Vietnam Auditing and Valuation Company Limited Address: 11th Floor, Song Da Building, 165 Cau Giay Street, Cau Giay Ward, Hanoi.	5/5

III. Supervisory Board (Six-Month Report)

1. Information about the members of the Supervisory Board

No.	Supervisory Board Member	Position	Date of commencement/cessation of membership in the Supervisory Board	Professional qualifications
1	Mrs. Bui Thi Hat	Head of the Supervisory Board	April 24, 2024	Bachelor
2	Ms. Dinh Thi Tram Anh	Member of the Supervisory Board	April 24, 2024	Bachelor
3	Ms. Truong Thi Nguyet Hoa	Member of the Supervisory Board	April 24, 2024	Bachelor

2. Supervisory Board Meeting

No.	Supervisory Board Member	Number of meetings attended	Meeting attendance rate	Voting ratio	Reasons for not attending the meeting.
1	Mrs. Bui Thi Hat	1/1	100%	100%	
2	Ms. Dinh Thi Tram Anh	1/1	100%	100%	
3	Ms. Truong Thi Nguyet Hoa	1/1	100%	100%	

3. The Supervisory Board's oversight activities cover the Board of Directors, the Executive Management, and shareholders.

In the first six months of 2026, the pharmaceutical industry was significantly affected by fluctuations in the global economy, particularly exchange rate volatility, rising prices of imported raw materials, and increased input costs, causing considerable difficulties for production and business operations.

In this context, the Board of Directors and the General Management Board have been proactive and flexible in their management and operations; implementing production and business plans in accordance with the actual situation; and effectively utilizing the company's management apparatus and resources. In addition, the company has actively expanded its market, ensuring employment, income, and benefits for its employees, contributing to maintaining stable operations and creating a foundation for sustainable development.

The Board of Directors has issued resolutions and decisions in accordance with the law, the Company's Articles of Association, and resolutions of the General Meeting of Shareholders.

The Board of Directors has managed production and business operations in accordance with the resolutions of the Board of Directors, fulfilling assigned tasks, and complying with legal regulations and the Company's Charter. Financial management, accounting, and internal control have been carried out in accordance with regulations.

Through its oversight activities, the Supervisory Board has found that the Board of Directors, the Management Board, and relevant departments have fully fulfilled their responsibilities and powers as stipulated by law and the Company's Charter. In the first six months of 2026, the Supervisory Board did not detect any serious violations affecting the legitimate rights and interests of the Company and its shareholders; the Supervisory Board agrees with the management and operational measures implemented by the Board of Directors and the Management Board.

4. The Supervisory Board coordinates its activities with those of the Board of Directors, the Executive Management, and other management personnel.

The coordination between the Supervisory Board, the Board of Directors, and the Executive Management Board is carried out closely, consistently, and in strict adherence to the resolutions of the General Meeting of Shareholders. In performing its supervisory function, the Supervisory Board is provided with all necessary documents and materials in a timely manner to monitor and evaluate the direction, management, and operation of production and business activities by the Board of Directors and the Executive Management Board.

IV. Executive Board

No.	Executive Board Member	Date of birth	Professional qualifications	Appointment date	Dismissal date
1	Mr. Nguyen Dinh Khai	December 5, 1975	Bachelor of Economics	May 28, 2019	
2	Ms. Bui Thi Loan	September 27, 1987	Pharmacist	January 1, 2022	

V. Chief Accountant

Full name	Date of birth	Professional qualifications	Appointment date
Ms. Tran Thi Ha Thu	May 9, 1988	Bachelor of Economics	August 1, 2019

VI. List of related parties of a public company (6-month report) and transactions of the Company's related parties with the Company itself.

1. List of related parties of the Company

No.	Name of organization/individual	Position at Company (if applicable)	The starting point is the person involved.	The point at which one is no longer involved.	Reason	Relationship with the company
1	Mr. Bui Xuan Huong	Chairman of the Board	April 24, 2024			Insider
2	Mr. Dinh Van Cuong	Non-executive board members	April 24, 2024			Insider
3	Mr. Nguyen Dinh Khai	Board Member and CEO	April 24, 2024			Insider
4	Ms. Lu Thi Khanh Tran	Non-executive board members	April 24, 2024	April 24, 2026		Insider
5	Mr. Le Van Hung	Non-executive board members	April 24, 2024			Insider
6	Mr. Vu Duc Canh	Non-executive board members	April 24, 2026			Insider
7	Mrs. Bui Thi Hat	Head of the Supervisory Board	April 24, 2024			Insider
8	Ms. Truong Thi Nguyet Hoa	Member of the Supervisory Board	April 24, 2024			Insider
9	Ms. Dinh Thi Tram Anh	Member of the Supervisory Board	April 24, 2024			Insider
10	Ms. Bui Thi Loan	Deputy General Manager	January 1, 2022			Insider
11	Ms. Tran Thi Ha Thu	Chief Accountant	August 1, 2019			Insider
12	Ms. Nguyen Thi Quynh Trang	Company Administrator	December 10, 2021			Insider

2. Transactions between the Company and its related parties; or between the Company and major shareholders, insiders, or related parties of insiders: not applicable.

3. Transactions between company insiders, related parties of insiders, and subsidiaries or companies controlled by the company: No

4. Transactions between the company and other parties.

4.1 . Transactions between the company and companies where members of the Board of Directors, members of the Supervisory Board, directors (General Director) and other related persons have been founding members or members of the Board of Directors, directors (General Director) in charge during the last three (03) years (calculated from the time of reporting): None

057:
ĐNG
Đ PH
IC PI
G UK
RIPH/
G - 1

4.2 . Transactions between the company and other companies where a related party of a member of the Board of Directors, a member of the Supervisory Board, or a director (General Director) is also a member of the Board of Directors or a director (General Director): No

4.3. Other transactions of the company (if any) that may provide material or non-material benefits to members of the Board of Directors, members of the Supervisory Board, Directors (General Director) and other managers: None

VI. Insider and related party stock transactions (6-month report)

1. List of insiders and related parties of insiders

No.	Name of organization/individual	Position at Company (if applicable)	Number of shares owned end of term	Ending stock ownership ratio	Note
1	Mr. Bui Xuan Huong	Chairman of the Board	1,371,800	6.38%	
1.1	Ms. Nguyen Thi Minh Huong		114,075	0.53%	Wife
1.2	Ms. Bui Huong Giang		0	0	Daughter
1.3	Mr. Bui Quy Son		0	0	Boy
1.4	Ms. Do Thi Minh		0	0	Mother
1.5	Mr. Bui Quang Chuc		0	0	Older brother
1.6	Mrs. Dinh Thi Tuat		0	0	Sister-in-law
1.7	Mr. Bui Xuan Duong		0	0	younger brother
1.8	Ms. Le Thi Hoa		0	0	sister-in-law
1.9	Ms. Bui Thi Phuong		0	0	Younger sister
1.10	Mr. Dinh Van Cuong		0	0	Brother-in-law
1.11	Ms. Bui Thi Hien		0	0	Younger sister
1.12	Mr. Nguyen Van Giao		0	0	Brother-in-law
1.13	Ms. Bui Thi Huong		0	0	Younger sister
1.14	Le Van Hung		0	0	Brother-in-law
2	Mr. Le Van Hung	Non-executive members of the Board of Directors	962,062	4.47%	
2.1	Ms. Le Thi Van		1,004,280	4.67%	Wife
2.2	Le Chi Thanh		0	0	Boy

No.	Name of organization/individual	Position at Company (if applicable)	Number of shares owned end of term	Ending stock ownership ratio	Note
2.3	Le Ha Nhi		0	0	Daughter
2.4	Le Ha Thu		0	0	Daughter
2.5	Mr. Le Thanh Toan		0	0	biological father
2.6	Ms. Nguyen Thi Mo		0	0	Mother
2.7	Mr. Nguyen Van Thang		0	0	Older brother
2.8	Ms. Nguyen Thi Van		0	0	Sister-in-law
2.9	Mr. Le Nguyen Vy		0	0	Father-in-law
2.10	Ms. Nguyen Thi Yen		0	0	Mother-in-law
2.11	Ms. Le Ngoc Khanh		0	0	sister-in-law
2.12	Ms. Le Van Khanh Linh		0	0	sister-in-law
3	Ms. Lu Thi Khanh Tran	Non-executive members of the Board of Directors	0	0	The date when you will no longer be an insider: April 24, 2026
3.1	Ms. Trinh Thi Minh Phuong		0	0	Mother
3.2	Mr. Tran Giang		0	0	Father-in-law
3.3	Mr. Tran Anh Dong		0	0	Husband
3.4	Tran Phuong Dinh		0	0	Boy
3.5	Tran Lu Duc Huy		0	0	Boy
3.6	Mr. Lu Minh		0	0	Older brother
3.7	Mrs. Nguyen Thi Cham		0	0	Sister-in-law
3.8	Codupha Central Pharmaceutical Joint Stock Company		0	0	Board Member
3.9	Vietnam Pharmaceutical		4,746,087	22%	Owner's representative

No.	Name of organization/individual	Position at Company (if applicable)	Number of shares owned end of term	Ending stock ownership ratio	Note
	Corporation – JSC				
10	Sanofi-Synthelabo Vietnam Pharmaceutical Joint Stock Company		0	0	Board Member
4	Mr. Dinh Van Cuong	Non-executive board members	1,199,170	5.58%	
4.1	Ms. Pham Thi Tu		0	0	Mother
4.2	Ms. Dinh Thi Minh		0	0	Older sister
4.3	Mr. Dinh Quang Trung		0	0	Older brother
4.4	Mr. Dinh The Anh		0	0	Younger brother
4.5	Mr. Dinh Tien Dung		0	0	Younger brother
4.6	Ms. Dinh Thi Ngoc Anh		0	0	Daughter
4.7	Ms. Dinh Bao Anh		0	0	Daughter
4.8	Ms. Dinh Minh Anh		0	0	Daughter
4.9	Mr. Dinh Duc Anh		0	0	Boy
4.10	Ms. Ho Kim Oanh		0	0	Wife
4.11	Mr. Pham Hong Thanh		0	0	Brother-in-law
4.12	Ms. Nguyen Thi Thuy		0	0	sister-in-law
4.13	Ms. Tran Thi Tuong Vi		0	0	sister-in-law
4.14	Huu Nghi Pharmaceutical Company Limited		0	0	Founding Member
5	Mr. Nguyen Dinh Khai	Board Member and CEO	3,150,850	14.66%	
5.1	Ms. Le Thanh Thuy		2,086,332	9.7%	Wife
5.2	Mr. Le Xuan Son		0	0	Father-in-law
5.3	Ms. Le Thi Thieu		0	0	Mother-in-law

No.	Name of organization/individual	Position at Company (if applicable)	Number of shares owned end of term	Ending stock ownership ratio	Note
5.4	Mr. Nguyen Dinh Khai		0	0	Younger brother
5.5	Ms. Hoang Thi Mo		951,622	4.42%	sister-in-law
5.6	Mrs. Trinh Thi Lo		0	0	Mother
5.7	Mr. Nguyen Dinh Khang		0	0	biological father
5.8	Nguyen Gia Bao		0	0	Boy
5.9	Nguyen Bao Ngoc		0	0	Daughter
6	Mr. Vu Duc Canh	Non-executive members of the Board of Directors	0	0	Start date for insider status: April 24, 2026
6.1	Mr. Vu Van Hanh		0	0	biological father
6.2	Ms. Nguyen Thi Yen		0	0	Mother
6.3	Mr. Vu Duc Thai		0	0	Younger brother
6.4	Ms. Nguyen Thi Hong Minh		0	0	sister-in-law
6.5	Ms. Hoang Thanh Thuy		0	0	Wife
6.6	Mr. Vu Duc Anh		0	0	Boy
6.7	Mr. Vu Duc Tri		0	0	Boy
6.8	Ms. Nguyen Thi Tam		0	0	Mother-in-law
6.9	Vietnam Pharmaceutical Corporation – JSC		4,746,087	22%	Owner's representative
6.10	Central Pharmaceutical Company No. 3		0	0	Board member, representing 350,000 shares, or 20% of Vinapharm.
6.11	Vietnam Medical Import-Export Joint Stock Company		0	0	Member of the Board of Directors. Represents 378,000 shares, or 18.85%, of Vinapharm.
7	Ms. Truong Thi Nguyet Hoa	Member of the Supervisory Board	0	0	

No.	Name of organization/individual	Position at Company (if applicable)	Number of shares owned end of term	Ending stock ownership ratio	Note
7.1	Mr. Pham Van Vuong		0	0	Husband
7.2	Mrs. Dao Thi Dinh		0	0	Mother
7.3	Mr. Truong Quang Chinh		0	0	Older brother
7.4	Mr. Truong Tuan Dat		0	0	Older brother
7.5	Pham Khanh Linh		0	0	Daughter
7.6	Pham Gia Hung		0	0	Boy
7.7	Ms. Ngo Bich Loan		0	0	Sister-in-law
8	Mrs. Bui Thi Hat	Head of the Supervisory Board	0	0	
8.1	Mr. Bui Thanh Liem		0	0	Husband
8.2	Bui The Lan		0	0	Boy
8.3	Bui Minh Thu		0	0	Daughter
8.4	Mr. Bui Quang Chuc		0	0	biological father
8.5	Mrs. Dinh Thi Tuat		0	0	Mother
8.6	Ms. Bui Thi Hao		0	0	Older sister
8.7	Mr. Bui Quang Sang		0	0	Father-in-law
8.8	Ms. Hoang Thi Hop				Mother-in-law
9	Ms. Dinh Thi Tram Anh	Member of the Supervisory Board	0	0	
9.1	Mr. Dinh Xuan Bien		0	0	biological father
9.2	Ms. Do Thi Tuyet		0	0	Mother
9.3	Mr. Dinh Manh Tuan		0	0	Older brother
9.4	Davina Pharmaceutical Joint		0	0	Members of the Supervisory Board

No.	Name of organization/individual	Position at Company (if applicable)	Number of shares owned end of term	Ending stock ownership ratio	Note
	Stock Company				
9.5	Central Pharmaceutical Company No. 3		0	0	Member of the Supervisory Board
10	Ms. Bui Thi Loan	Deputy General Manager	7,540	0.03%	
10.1	Mr. Do Ngoc Dang		0	0	Husband
10.2	Mr. Bui Van Tam		0	0	biological father
10.3	Ms. Do Thi Binh		0	0	Mother
10.4	Ms. Bui Thi Thu Trang		0	0	Younger sister
10.5	Mr. Bui Van Thai		0	0	Younger brother
10.6	Ms. Do Thi Ly		0	0	Mother-in-law
10.7	Mr. Do Manh Truong		0	0	My husband
10.8	Ms. Pham Thi Thu Hoai		0	0	Sister-in-law
10.9	Mr. Do Xuan Chinh		0	0	sister-in-law
10.10	Ms. Hoang Thi Thu Hang		0	0	sister-in-law
10.11	Do Hong Phuc		0	0	Boy
10.12	Do Dang Khoi		0	0	Boy
11	Ms. Tran Thi Ha Thu	Chief Accountant	2,650	0.01%	
11.1	Mr. Tran Tuan Nghia		0	0	biological father
11.2	Mrs. Dinh Thi Nhuan		0	0	Mother
11.3	Mr. Nguyen Xuan Thuy		2,312	0.01%	Husband
11.4	Mr. Nguyen Xuan Hinh		0	0	Father-in-law
11.5	Mrs. Bui Thi Que		0	0	Mother-in-law
11.6	Nguyen Tran Duc Thinh		0	0	Boy
11.7	Nguyen Tran Minh Thu		0	0	Daughter
11.8	Ms. Tran Thi Thuy Linh		0	0	Younger sister
11.9	Mr. Phan Tuan Anh		0	0	Brother-in-law

No.	Name of organization/individual	Position at Company (if applicable)	Number of shares owned end of term	Ending stock ownership ratio	Note
12	Ms. Nguyen Thi Quynh Trang	Company Administrator	0	0	
12.1	Mr. Nguyen Thanh Quang		0	0	biological father
12.2	Ms. Nguyen Thi Yen		0	0	Mother
12.3	Mr. Nguyen Thanh Trung		0	0	Older brother
12.4	Ms. Vu Thi Hoang Huong		0	0	Sister-in-law
12.5	Nguyen Tai Gia Hung		0	0	Boy

2. Transactions by insiders and related parties involving the company's stock.

No.	Performed by transaction	Relationships with insiders	Number of shares owned at the beginning of the period		Number of shares held at the end of the period		Reasons for increase or decrease (buying, selling, conversion, bonus, etc.)
			Number of shares	Proportion	Number of shares	Proportion	
1							

Recipient:

- Hanoi Stock Exchange
- Save

CHAIRMAN OF THE BOARD OF DIRECTORS



 CÔNG TY
 CỔ PHẦN
 DƯỢC PHẨM
 TRUNG ƯƠNG 3
 (FORIPHARM)

01-C.T.C.P
 N
 AM
 VG 3
 3M
 HAI PHONG

Pharmacist Bui Xuan Huong